Zhang Han, Li Gang, Li Qiangqiang, Zuo Yansong, Wang Qiang
Pediatric Heart Center, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China.
Rev Cardiovasc Med. 2024 Jul 8;25(7):253. doi: 10.31083/j.rcm2507253. eCollection 2024 Jul.
To evaluate the effectiveness of the surgical approach in patients with congenital heart disease and pulmonary hypertension (PH).
This was a retrospective clinical review of patients with congenital heart disease and PH who underwent pulmonary artery banding (PAB) at our institution between January 2013 and January 2023.
We identified 219 patients (53.4% males) with a median age of 7 (4.0-15.0) months and a median weight of 6.8 (5.2-9.0) kg at the time of PAB. The median hospital stay was 7.0 (5.0-10.0) days. The in-hospital mortality rate was 4.6%. The median follow-up was 33.0 (17.0-61.0) months. Survival rates were 96.9 2.5% at 60 months and 92.1 6.9% at 120 months post-PAB. 43.8% of patients had a de-banding procedure, and 147 (79.0%) patients received a second-stage procedure (34.7% univentricular, 65.3% biventricular). The mortality rate between stages was 4.3%. 21 (9.6%) patients reached a third-stage procedure. The overall mortality rate was 9.1%.
PAB is an acceptable strategy for patients with congenital heart disease complicated with PH. The results and outcomes of subsequent univentricular or biventricular procedures are generally good.
评估手术方法对先天性心脏病合并肺动脉高压（PH）患者的有效性。
这是一项对2013年1月至2023年1月在我院接受肺动脉环缩术（PAB）的先天性心脏病合并PH患者的回顾性临床研究。
我们确定了219例患者（男性占53.4%），PAB时的中位年龄为7（4.0 - 15.0）个月，中位体重为6.8（5.2 - 9.0）kg。中位住院时间为7.0（5.0 - 10.0）天。住院死亡率为4.6%。中位随访时间为33.0（17.0 - 61.0）个月。PAB后60个月的生存率为96.9±2.5%，120个月时为92.1±6.9%。43.8%的患者进行了解环手术，147例（79.0%）患者接受了二期手术（单心室占34.7%，双心室占65.3%）。各阶段之间的死亡率为4.3%。21例（9.6%）患者进行了三期手术。总死亡率为9.1%。
PAB是先天性心脏病合并PH患者可接受的治疗策略。后续单心室或双心室手术的结果和预后总体良好。
